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We report a single institution phase II study of gemcitabine 1200mgm
 2 i.v. on days 1 and 8 and capecitabine 1300mgm
 2 twice
daily on days 1–14 of each 3-week cycle in patients with metastatic renal carcinoma. Patients had a WHO performance status of 0, 1
or 2. Of the 21 enrolled patients, 19 had received prior immunotherapy or chemoimmunotherapy. All had progressive disease at
study entry. In all,19 patients had multiple sites of disease. The median duration of metastatic disease was 12.3 months (range 1.2–
78.1 months). Three of the 19 evaluable patients achieved a partial response to treatment, with no complete responses, producing an
objective overall response rate of 15.8% (95% CI, 3.4–39.6%). The median time to disease progression was 7.6 months, and median
overall survival was 14.2 months. Treatment was reasonably well-tolerated, neutropenia being the most frequently observed grade 3
or 4 toxicity, occurring in 57% of patients. Other side effects were consistent with the established toxicity profile of the two drugs,
including diarrhoea, palmar-plantar erythema, fatigue, nausea, vomiting and infection. This combination of gemcitabine and
capecitabine has modest activity in immunotherapy-refractory metastatic renal carcinoma with manageable toxicity.
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Metastatic renal cell carcinoma has a very poor prognosis with a
median survival duration of approximately 9 months. A minority
of patients experience a response to immunotherapy with
interleukin-2 or interferon-alpha, or a combination of these
agents. However, some patients have good quality responses with
prolonged disease-free survival, and for this reason immunother-
apy has remained the standard first-line treatment for this disease
(Medical Research Council Renal Cancer Collaborators, 1999).
Combinations of immunotherapy and 5-fluorouracil (5-FU)
chemotherapy have produced consistently higher response rates
of 20–39% in previously untreated patients, but at the expense of
additional toxicity (Atzpodien et al, 1995, ; Lopez Hanninen et al,
1995; Tourani et al, 1998; Allen et al, 2000; van Herpen et al, 2000).
As yet there is no randomised evidence supporting the superiority
of this approach over standard immunotherapy. Patients failing to
respond to immunotherapy have a generally poor outlook. At
present, there is no standard therapeutic approach for this group
of patients. Single-agent chemotherapy with a variety of drugs has
failed to produce response rates much greater than 5% (Yagoda
et al, 1993). For instance, single-agent gemcitabine produced
response rates of 6 and 8.1% in two phase II trials (Mertens et al,
1993; De Mulder et al, 1996). There have been no published clinical
trials of single-agent capecitabine in metastatic renal carcinoma,
but single-agent 5-FU has been studied, producing response rates
of 5-10% (Yagoda et al, 1993; Kish et al, 1994).
More interesting activity was observed with combination
chemotherapy comprising continuous infusion 5-FU and weekly
gemcitabine. This regimen produced a 17% response rate among
41 predominantly immunotherapy or chemotherapy pretreated
patients with metastatic renal cell carcinoma in a phase II study
undertaken at the University of Chicago Hospitals (Rini et al,
2000). This regimen has the drawback of requiring an in-dwelling
intravenous catheter together with an ambulatory infusion pump
for chemotherapy administration.
Capecitabine is an orally available fluoropyrimidine carbonate
activated in a three-step enzymatic conversion to 5-FU. The final
step of this conversion is catalysed by the enzyme thymidine
phosphorylase, which is overexpressed in tumour cells (Mori et al,
2000), thus theoretically providing a degree of specificity for
tumour over normal tissue. Capecitabine has replaced 5-FU in
chemoimmunotherapy regimens without compromising activity in
metastatic renal cell carcinoma (Oevermann et al, 2000). The
combination of gemcitabine and 5-fluoro-20-deoxyuridine (an
intermediate metabolite of capecitabine) has demonstrated syner-
gistic activity in vitro (Ren et al, 1998). Several phase I trials have
evaluated combinations of gemcitabine and capecitabine, and have
shown that full single-agent doses can be delivered in combination
(Schilsky et al, 2002; Hess et al, 2003; Scheithauer et al, 2003). This
single institution phase II trial aimed to evaluate the activity and
toxicity of a combination of gemcitabine and capecitabine in
patients with metastatic renal cancer refractory to or unsuitable for
immunotherapy.
PATIENTS AND METHODS
Protocol population
Patients were eligible for this trial if they had histologically
or cytologically verified metastatic renal carcinoma of any
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lhistological subtype; one or more clinically or radiologically
measurable lesions of at least 1cm diameter outside previous
radiotherapy fields; Eastern Cooperative Oncology Group
(ECOG) performance status (PS) 0–2; age greater than or equal
to 18years; life expectancy of at least 12 weeks; and had adequate
organ function defined by an absolute neutrophil count of at
least 1.5   10
9l
 1; platelet count of at least 100 x 10
9l
 1;
haemoglobin at least 10gdl
 1; serum creatinine less than three
times the upper normal limit or creatinine clearance at least
50mlmin
 1; ALT, AST and alkaline phosphatase less than 1.5
times the upper normal limit. Patients were allowed to have
received prior treatment for metastatic renal carcinoma including
interferon-alpha, interleukin-2, or combined biochemotherapy
including bolus 5-FU, but were not allowed to have received
gemcitabine, capecitabine or infused delivery of 5-FU previously.
Patients were also excluded from entry to this trial if they had not
received immunotherapy for metastatic renal carcinoma and were
suitable for such treatment, if they had severe or uncontrolled
nonmalignant disease, or if they had a history of a previous
malignancy likely to interfere with protocol treatment or assess-
ment of outcome. Pregnant or lactating women were also excluded
from participation, and all patients with reproductive potential
were required to use an effective contraceptive method if they were
sexually active. All patients provided written informed consent to
participate in the trial, which was approved by the Royal Marsden
Hospital Scientific Research and Ethics committees (Protocol
Number 2028).
Study design
This was an open-label, single institution, nonrandomised phase II
study. The chemotherapy regimen was administered on an
outpatient basis and comprised gemcitabine 1200mgm
 2 i.v. over
30min on days 1 and 8 and oral capecitabine 1300mgm
 2 twice
daily for 14 days of a 21-day cycle for up to six cycles of treatment.
Patients were restaged with physical examination, computed
tomography (CT) scan and where applicable radioisotope bone
scan after three and six cycles, or in the event of clinical suspicion
of disease progression. Treatment was discontinued in the event of
disease progression, unacceptable toxicity (including any grade 4
nonhaematological toxicity or symptomatic grade 4 haemato-
logical toxicity), or at the patient’s request. In the event of grade 3
nonhaematological toxicity other than palmar-plantar syndrome,
treatment was stopped and the next cycle delayed until recovery to
baseline level. Treatment was then commenced with a 25–50%
reduction in gemcitabine and/or capecitabine doses at the
investigator’s discretion.
In the case of palmar plantar syndrome, treatment was stopped
until recovery, and patients were commenced on pyridoxine 50mg
three times a day. For subsequent cycles, no adjustment to the
gemcitabine dose was made. For grade 2 toxicity or the first
appearance of grade 3 toxicity, the capecitabine dose was reduced
by 25%. For grade 4 toxicity or recurrent grade 3 toxicity the
capecitabine dose was reduced by 50%.
Delays and dose reductions were also instituted in the event of
haematological toxicity as follows. Day 1 gemcitabine and
capecitabine treatment was delayed for 1 week if the total white
cell count was less than 3.0   10
9l
 1 or the platelet count was less
than 100   10
9l
 1. Day 8 gemcitabine treatment was dose-
reduced by 25% if the total white cell count was in the range
2.0–2.5   10
9l
 1 or the platelet count was in the range 50–75  
10
9l
 1. A total white cell count or platelet count below these ranges
required omission of the Day 8 gemcitabine, and doses of
gemcitabine on subsequent cycles were administered with a
25% dose-reduction. In the event of a delay in treatment due to
toxicity of greater than 3 weeks, the patient was removed from the
study.
Response assessment
A complete response was defined as the complete disappearance of
all evidence of disease determined by two observations not less
than 4 weeks apart. A partial response was defined as a decrease of
50% or more in the sum of the products of the two maximum
perpendicular diameters of measurable disease for at least 4 weeks,
without the appearance of new lesions, or progression of any
individual lesion. Progressive disease was defined as a 25% or
more increase in the sum of the products of the two maximum
perpendicular diameters of measurable lesions, or the develop-
ment of any new lesions. Stable disease was defined as any change
less than that satisfying the criteria for complete response, partial
response or progressive disease over a period of at least 4 weeks.
No external verification of response was employed. Time to disease
progression was measured from the date of study enrolment to the
date of progressive disease. Duration of response was measured
from the date objective measurement criteria were met for
complete or partial response to the date of disease progression.
Overall survival was measured from the date of study enrolment to
the date of death from any cause.
Statistical considerations
The primary end point of this phase II trial was to determine the
response rate of gemcitabine and capecitabine in a population of
patients with metastatic renal cell carcinoma refractory to or
unsuitable for treatment with immunotherapy. The reported
response rate to the combination of gemcitabine and 5-FU in this
setting was 17% (95% CI, 8–34%) (Rini et al, 2000), while no other
second-line agent has consistently produced a response rate
greater than 10%. This trial adopted a two-stage Gehan design
(Gehan, 1979), enrolling 14 patients in the first stage. The
treatment would be rejected as insufficiently active if no responses
were observed in this stage. In the event of 1, 2, 3, 4, or 5 or more
responses among the first 14 patients, 1, 4, 6, 9, or 11 patients,
respectively, would be entered in the second stage. This design has
a less than 5% probability of rejecting a treatment with a true
response rate of 20%, and provides an estimate of the response rate
with a standard error of approximately 10%.
RESULTS
Patient characteristics
This study accrued patients between March 2002 and March 2003.
Three responses were observed during the first phase, leading to
the recruitment of an additional six patients according to the trial
design. One patient was removed from study due to an incidental
chest infection unrelated to study medication before completion of
the first cycle. This patient was replaced resulting in 21 patients
being enrolled in all. The baseline demographic and clinical
characteristics of the patient population are listed in Table 1. The
majority of patients had received one prior treatment regimen,
comprising either single agent interferon or a chemoimmuno-
therapy regimen incorporating bolus 5-FU, interferon and IL-2.
However, five patients had received two prior treatment regimens,
and one patient had received three prior treatment regimens. Only
two patients had received no prior treatment for metastatic renal
carcinoma: one had previously undergone cadaveric renal
transplantation and was considered unsuitable for immuno-
therapy; the second had a diagnosis of transitional cell carcinoma
of the renal pelvis for which immunotherapy is not an appro-
priate treatment. In view of the different natural history and
chemosensitivity of transitional cell carcinoma and epithelial renal
cell carcinoma, this patient who achieved a partial response to
therapy is considered a protocol violation. We report toxicity data
relating to this patient, but not outcome data. The median time
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lsince diagnosis of metastatic disease of 12.3 months suggests a
patient population that may have relatively indolent disease.
However, 38% of patients enrolled had liver metastases, while only
one patient had metastatic disease confined to the lungs.
Furthermore, considering the prognostic index developed by
Motzer et al, 2004, incorporating the recognised adverse prog-
nostic factors of poor performance status, anaemia, and hyper-
calcaemia, 43% of this patient cohort fall into the intermediate and
29% into the poor prognosis categories.
Response to treatment
One patient was not assessable for response due to the
development of a severe chest infection during the first cycle of
treatment in the absence of neutropenia. This delayed resumption
of chemotherapy beyond the protocol-stipulated limits, and the
patient was removed from study. A second patient died after a
single dose of gemcitabine, without evidence of chemotherapy-
related toxicity. This patient was also not assessable for response,
but was included in the intent-to-treat analysis, and was classified
as having progressive disease. Among the 19 patients assessed for
response, there were no complete responses, and three partial
responses (objective response rate, 15.8% (95% CI, 3.4–39.6%). In
all, 10 patients (53%) had stable disease, and six patients (32%)
experienced disease progression on treatment. Among the three
responding patients, the response duration was 5.6, 5.8 and 18.8
months, respectively. The clinical characteristics of these three
patients are listed in Table 2. Of interest, responses were observed
in three of four patients with granular cell histology (including one
patient with mixed clear cell and granular cell histology), whereas
none of the four patients with papillary histology responded to this
treatment. The prognostic category of one responding patient was
favourable (no adverse risk factors), and of the remaining two was
intermediate (one adverse risk factor in each case) (Motzer et al,
2004).
Kaplan – Meier curves for progression-free and overall survival
are shown in Figure 1. With a median follow-up duration for
surviving patients of 20.8 months, two patients remain free of
disease progression and the median progression-free survival is 7.6
months. In all, 11 patients have died. The median overall survival
duration is 14.2 months, and the estimated proportion of patients
remaining alive at 1 year is 58%.
Toxicity
Toxicity data have been analysed for all 21 patients enrolled in the
study, who received a total of 89 cycles of therapy. Overall worst
grade of haematological toxicity was grade 0 in one patient, grade 2
in seven patients, grade 3 in nine patients and grade 4 in four
patients. Overall worst grade of nonhaematological toxicity was
grade 2 in six patients, grade 3 in 12 patients and grade 4 in three
patients. The rate of grade 2–4 toxicity is shown in Table 3. The
most frequently observed grade 3 or 4 toxic effects were
neutropenia in 57% of patients, infection in 33% (neutropenic
sepsis in 14%), thrombocytopenia in 24%, palmar plantar
erythema in 19%, diarrhoea in 14% and thromboembolism in
14%. Despite these relatively high frequencies of severe toxicity per
patient, adherence to the protocol-stipulated treatment delays and
dose reductions resulted in low rates of severe toxicity per
Table 1 Baseline demographic and disease characteristics
Number of patients enrolled 21
Median age (range) 57 (36–2) years
Sex
Male 15
Female 6
Performance status
05
11 3
23
Histology
Clear cell 11
Mixed clear cell and granular cell 2
Granular cell 2
Papillary 4
Oncocytic 1
Transitional cell 1
Prior therapy
Nephrectomy 20
Chemoimmunotherapy 5
Immunotherapy 14
Radiotherapy 5
Median number of prior systemic therapies (range) 1 (0–3)
Involved sites of disease
Lung 13
Liver 8
Lymph nodes 11
Bone 7
Renal bed 6
CNS 1
a
Median number of sites involved (range) 2 (1–5)
Median time since diagnosis of metastatic disease in months
(range)
12.3 (1.2–78.1)
Median time since diagnosis in months (range) 18.2 (4.3–297.2)
Number of poor prognostic factors
b
06
19
25
31
aBrain metastasis previously resected.
bMotzer et al (2004).
Table 2 Characteristics of responding patients
Patient no. 6 8 12
Sex Male Female Male
Age 46 55 44
Prior nephrectomy Yes Yes Yes
Histology Mixed clear cell and granular Granular Granular
Prior systemic therapy Atzpodien regimen
a 1. 5-FU + IL-2 Atzpodien regimen
a
2. IL-2 + IFN
Time since diagnosis of metastases (months) 12 13 7
Metastatic sites Lung Lung, lymph nodes, bone Lung, liver
Performance status 0 1 1
Number of poor prognostic factors 1 0 1
Duration of response (months) 5.6 5.8 18.8
b
Time to disease progression (months) 7.9 7.6 20.8
b
Post-trial therapy BAY 43-9006
c Provera None
Overall survival (months) 21.5
d 9.9 20.8
d
aIL-2, IFN-alpha and 5-FU (Atzpodien et al, 2001).
bRemains free of disease progression on follow-up.
cPhase II trial of a B-raf kinase inhibitor.
dRemains alive on follow-up.
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lchemotherapy cycle. The most frequently observed grade 3 or 4
toxicity per cycle was neutropenia, occurring in 24% of cycles.
Grade 3 or 4 infection was recorded in only 9% of cycles
(neutropenic sepsis in 3% of cycles), thrombocytopenia in 7% of
cycles, and all other grade 3 or 4 toxicity was observed in fewer
than 5% of cycles. Clinical sequelae resulting from myelosuppres-
sion included three cases of grade 3 infection in association with
grade 3 or 4 neutropenia. Three cases of haemorrhage in
association with grade 3 or 4 thrombocytopenia were also
observed. However, blood transfusion was only required in one
case, and the relationship between the episode of haemorrhage
(epistaxis) and the development of anaemia requiring blood
transfusion was not established.
Three cases of venous thromboembolism occurred during
protocol therapy. Two cases were uncomplicated deep vein
thrombosis, and the third was a case of pulmonary embolism.
All were treated successfully with standard anticoagulation and
were able to continue chemotherapy on study, although frequent
monitoring of the INR was required due to the metabolic
interaction between capecitabine and warfarin. One patient died
during protocol treatment, after a single dose of gemcitabine.
There was no evidence of treatment-related toxicity in this case,
but a post-mortem examination was not performed. Four patients
were removed from study because of toxicity. One patient had
prolonged grade 3 or 4 neutropenia and thrombocytopenia, and
recurrent diarrhoea despite dose reduction. One patient had
recurrent grade 3 palmar plantar erythema despite dose reduction.
One patient developed ischaemic chest pain, attributed to
capecitabine therapy, and the final patient developed prolonged
pyrexia of unknown origin, without microbiological evidence of
infection.
Dose intensity
Treatment interruptions and dose reductions were frequently
required, only two patients completing six cycles of treatment
without any modification in dose or schedule. Overall, 72% of
cycles were delivered on schedule, and 52% of cycles were
delivered at full dose, while 38% of cycles were delivered on
schedule and at full dose. The total number of days delay per
patient is shown in Figure 2, and the doses of capecitabine and
gemcitabine delivered per cycle are shown in Figure 3. Using the
formula: dose intensity ¼ (cumulative dose received/duration of
treatment)/(planned cumulative dose/planned duration of treat-
ment), the achieved dose intensity for gemcitabine was 0.8, and for
capecitabine was 0.76. Taking into account cycles of chemotherapy
omitted after discontinuation of therapy due to toxicity, achieved
dose intensities were 0.7 for gemcitabine and 0.66 for capecitabine.
DISCUSSION
This phase II trial has demonstrated modest activity of the
combination of gemcitabine and capecitabine in a population of
patients with immunotherapy-refractory metastatic renal carcino-
ma. While comparisons between uncontrolled phase II trials must
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Figure 1 Progression-free and overall survival (n ¼ 20).
Table 3 Adverse event
Grade 2 Grade 3 Grade 4
Toxicity No (%) patients % cycles No (%) patients % cycles No (%) patients % cycles
Neutropenia 4 (19) 23 9 (43) 20 3 (14) 5
Thrombocytopenia 0 2 4 (19) 6 1 (5) 1
Anaemia 10 (38) 14 2 (10) 2 0 0
Infection 6 (29) 16 7 (33) 9 0 0
Palmar-plantar erythema 5 (24) 9 4 (19) 5 0 0
Diarrhoea 2 (10) 2 3 (14) 5 0 0
Nausea and vomiting 6 (29) 7 1 (5) 1 0 0
Lethargy 5 (24) 8 2 (10) 4 0 0
Thromboembolism 0 0 1 (5) 1 2 (10) 2
Skin rash 4 (19) 6 1 (5) 2 1 (5) 1
Haemorrhage 2 (10) 4 1 (5) 1 0 0
Dyspnoea 6 (29) 12 1 (5) 1 0 0
Mood alteration 0 1 1 (5) 1 0 0
Renal impairment 1 (5) 1 2 (10) 2 0 0
Hepatic dysfunction 1 (5) 2 1 (5) 1 0 0
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Figure 2 Delays to chemotherapy delivery.
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lbe undertaken with caution, particularly in a disease with a
variable natural history such as renal cancer, the response rate of
15.8% observed in patients with epithelial renal cell carcinoma in
this trial is comparable to that produced by the combination of
gemcitabine and protracted venous infusion 5-FU in the University
of Chicago study (Rini et al, 2000), and is among the highest
reported for any treatment regimen in this patient population.
Similarly, the median time to disease progression of 7.6 months is
clinically meaningful. The median overall survival duration of 14.2
months is longer than expected for this patient population, and
may reflect patient selection for a phase II trial or a contribution of
subsequent treatment as well as activity of the regimen under
evaluation.
This chemotherapy regimen was generally well tolerated, with
little unexpected toxicity. The largely nonoverlapping toxicity
profile of the two drugs allowed the delivery of full single-agent
doses of capecitabine and gemcitabine in combination. The most
common toxic effect was myelosuppression, and this toxicity was
the main reason for treatment interruption and dose reduction.
The planned dose intensity of gemcitabine in this study was
833mgm
 2week
 1 in contrast to the University of Chicago study
of gemcitabine and 5-FU where the planned dose intensity of
gemcitabine was 600mgm
 2week
 1. This difference probably
accounts for the higher rates of myelosuppression observed in our
study. However, despite dose reductions and delays, the achieved
dose intensity of gemcitabine was 666mgm
 2week
 1. Clinical
sequelae of myelosuppression were infrequent and manageable in
all cases, only one patient requiring removal from study because of
persistent neutropenia and thrombocytopenia. The 14% incidence
of venous thromboembolism observed during this study is not
unexpected in this patient cohort. A previous phase II trial of
gemcitabine, 5-FU and thalidomide in patients with metastatic
renal carcinoma reported a 48% rate of venous thromboembolic
complications, which the authors attributed largely to the addition
of thalidomide to the regimen (Desai et al, 2002).
On the basis of this trial, the combination of gemcitabine and
capecitabine is a reasonable treatment option for patients with
metastatic renal carcinoma following the failure of standard
immunotherapy. However, results of chemotherapy in this group
as a whole remain disappointing. There is a suggestion from our
results that the granular-cell subtype of renal carcinoma may be
more sensitive to gemcitabine and capecitabine chemotherapy
than other histological types. This is in contrast with other reports
suggesting greater chemosensitivity of papillary renal carcinoma to
topotecan (Ramp et al, 2001); in our study, none of four patients
with this histological subtype achieved a response to treatment. It
will clearly be important to attempt to understand fundamental
differences between these diseases, which may facilitate the
rational selection of therapy for these patients. These observations
support the concept of targeted cytotoxic therapy for renal
carcinoma. A phase II trial examining the multitargeted antifolate
pemetrexed in the treatment of metastatic renal carcinoma
demonstrated a response rate of 9% (Thodtmann et al, 2003).
The combination of pemetrexed and gemcitabine would be of
interest for further study. In our view, such trials should
incorporate assessment of the expression of key target enzymes
such as thymidylate synthase, dihydropyrimidine dehydrogenase
and glycinamide ribonucleotide formyl transferase (GARFT).
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